Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1994-08-18
1997-01-14
Russel, Jeffrey E.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 21, A61K 3817
Patent
active
055939643
ABSTRACT:
A method of treating septic shock in a mammal by preventing in vivo polymerization of actin in the mammal. An actin antipolymerizer such as thymosin .beta..sub.4 (T.beta..sub.4) is administered to the mammal so as to treat septic shock in the mammal. The amount of T.beta..sub.4 administered is sufficient to reduce levels of IL-1.alpha., TNF.alpha., PAF, Tx.beta..sub.2 and/or 6-keto-PGF.sub.1 .alpha. in the blood of the mammal. Also disclosed is a method of preventing septic shock in a mammal following endotoxin introduction in the mammal by administrating an actin antipolymerizer such as T.beta..sub.4.
REFERENCES:
patent: 4297276 (1981-10-01), Goldstein et al.
patent: 4395404 (1983-07-01), Low et al.
patent: 5055447 (1991-10-01), Palladino et al.
patent: 5260224 (1993-11-01), Stossel et al.
patent: 5464817 (1995-11-01), Stossel et al.
Lee et al., New England Journal of Medicine vol. 326 pp. 1335-1341 (1992, May).
Safer, D. and Nachmias, V. T., BioEssays, 16:473-479 (1994).
Stossel, Thomas P., The Machinery of Cell Crawling, Scientific American, pp. 54-63 (Sep. 1994).
Ishitsuka et al., "Protective Activity of Thymosin Against Opportunistic Infections in Animal Models", Cancer Immunology Immunotheraphy, 14:3, pp. 145-150, Mar. 1983.
Ashkenazi et al., "Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin", Proc. Natl. Acad. Sci. USA, 88:23, pp. 10535-10539, Dec. 1, 1991.
Watt et al., "Alterations in plasma levels and complexing of Gc (vitamin D-binding protein) in rats with endotoxic shock", Biological Abstracts, 88:7, Abstract No. 75029, 1989 (Circ Shock, 28:3, pp. 279-292, 1989).
Cross et al. Infection and Immunity vol. 61(7) pp. 2741-2747 (Jul. 1993).
Biotechnology Newswatch, Aug. 1, 1994 pp. 1 and 4.
Fitzer-Schiller, Washington Post, Jan. 19, 1993 p. D3.
Sawada et al., "Protection Against Infection with Pseudomonas aeruginosa by Passive Transfer of Monoclonal Antibodies to Lipopolysaccharides and Outer Membrane Proteins", J. Inf. Dis., vol. 150, pp. 570-576 (1984).
Teng et al., "Protection Against Gram-negative Bacteremia and Endotoxemia With Human Monoclonal IgM Antibodies" Proc. Nat'l Acad. Sci., vol. 82, pp. 1790-1794 (1985).
Baumgartner et al., "Association Between Protective Efficacy of Anti-Lipopolysaccharide (LPS) Antibodies and Suppression of LPS-Induced Tumor Necrosis Factor .alpha. And Interleukin 6", J. Exp. Med., vol. 171, pp. 889-895 (1990).
Safer, D. et al, "Thymosin .beta..sub.4 and F.sub.x, An Actin-Sequestering Peptide, Are Indistinguishable," J. Bio. Chem., vol. 266, pp. 4029-4032 (1991).
Sanders, M., et al. "Thymosin .beta..sub.4 (F.sub.x Peptide) is a Potent Regulator of Actin Polymerization in Living Cells," Proc. Nat'l. Acad. Sci., vol. 89, pp. 4678-4682 (1992).
Webster's Third New International Dictionary, p. 1798 (1986).
Dorland's Illustrated Medical Dictionary, 26th ed., p. 1026 (not dated).
T. Low et al., "Thymosins: Structure, Function and Therapeutic Applications", Thymus 6, 27 42 (1984), pp. 27-42.
Fagarasan Mirela O.
Goldstein Allan L.
Russel Jeffrey E.
The George Washington University Medical Center
LandOfFree
Method of treating septic shock by preventing actin polymerizati does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating septic shock by preventing actin polymerizati, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating septic shock by preventing actin polymerizati will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1388182